Cytek Biosciences (CTKB) news
Recent news
CyteK Biosciences: jury awarded past damages consisting of $20 mln in lost profits and $36 mln in royalties
AInvest Wire · Aug 21, 2026CyteK Biosciences: jury finds in CyteK’s favor on three of four asserted claims; to challenge remaining finding
In a recent patent litigation case, Beckman Coulter, Inc. v. Cytek Biosciences, Inc., a jury found in favor of Cytek Biosciences on three of the four asserted claims. The decision, reached in the U.S. District Court for the District of Delaware (C.A. No. 24-945-CFC), marks a significant development…
AInvest Wire · Aug 21, 2026CyteK Biosciences Q2 EPS USD -0.09
Cytek Biosciences, Inc. (Nasdaq: CTKB) reported second-quarter 2026 earnings per share (EPS) of -$0.09, reflecting a net loss for the period. The results were released ahead of scheduled earnings call and investor update on August 5, 2026. This follows the company’s first-quarter 2026 financial…
AInvest Wire · Aug 5, 2026CyteK Biosciences Q2 adjusted gross margin 61% (corrects amount)
AInvest Wire · Aug 5, 2026Cyient - public announcement-buyback of shares
Cyient Limited announced on April 23, 2026, that its Board of Directors has approved a buyback of equity shares through a tender offer at a price of ₹1,125 per share, with an aggregate consideration not exceeding ₹720 crore . The move reflects the Board’s confidence in the company’s fundamentals…
AInvest Wire · Jun 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.